Related Experiment Video
Updated: Aug 6, 2026
10:40
Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
Published on: August 4, 2012
Driving in hepatic encephalopathy
Keith Brick1,2, Rohit Gupta1,2
1Sunshine Coast University Hospital, Birtinya, Queensland, Australia.
Internal Medicine Journal
|July 20, 2026
Summary
Hepatic encephalopathy (HE) impairs driving safety due to cognitive deficits. This study proposes a risk-stratified framework for managing driving restrictions in patients with HE, balancing safety and autonomy.
Area of Science:
- Neurology
- Hepatology
- Public Health
Background:
- Hepatic encephalopathy (HE) is a neuropsychiatric complication of cirrhosis.
- HE causes cognitive and psychomotor impairments affecting driving safety.
- Current driving guidelines for HE patients are inconsistent.
Purpose of the Study:
- To review the impact of overt (OHE) and covert HE on driving performance.
- To outline a risk-stratified framework for managing driving in HE patients.
Main Methods:
- Literature review on HE and driving.
- Development of a risk-stratified management framework.
Main Results:
- HE significantly impairs attention, visuospatial ability, reaction time, and executive function.
- Impaired driving performance in HE patients increases motor vehicle collision risk.
- No standardized Australian guidelines exist for driving with HE.
Conclusions:
- A pragmatic, risk-stratified framework is proposed for driving restrictions in HE.
- The framework involves time-limited restrictions and conditional return to driving.
- This approach balances public safety with patient autonomy and quality of life.
More Related Videos
Related Concept Videos
01:29Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:16Hepatic Drug Excretion: Influencing Factors
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...